先達股份(603086.SH):濰坊先達取得年產3500原藥項目環評批覆
格隆匯9月1日丨先達股份(603086.SH)公佈,近日,公司全資子公司濰坊先達化工有限公司(以下簡稱“濰坊先達”)收到濰坊市生態環境局《關於濰坊先達化工有限公司年產3,500噸原藥項目環境影響報告書的批覆》。
該項目建設地點位於濰坊先達現有廠區內,項目包括“年產300噸甲咪唑煙酸、年產1,200噸咪唑乙煙酸、年產2,000噸烯草酮”,項目配套設施依託現有設施,項目總投資預計5,000萬元。
該批覆同意濰坊先達在現有廠區內建設年產3500原藥項目,並且落實批覆中提出的各項環保措施和要求,嚴格執行環境保護“三同時”制度,並按規定進行項目竣工環境保護驗收。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.